検索結果

Product Development Policy | Research & Development | SENJU Pharmaceutica

etina, cause bleeding and edema. In recent drug therapies, intravitreal injection of antibody drugs targeting the vascular endothelial growth factor (VEGF) protein, which increases angiogenesis and le...

s first successful clinical development of a TRPV1 antagonist for DED, completed in Japan. DED, the target disease of Avarept®, is defined as “A multifactorial disease characterized by an unstable tea...

s first successful clinical development of a TRPV1 antagonist for DED, completed in Japan. DED, the target disease of Avarept®, is defined as “A multifactorial disease characterized by an unstable tea...

c atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target. Retina. 2017;37(5):819-835. 2 Cheung, C.M.G., Chen, Y., Holz, F.G. et al. Geographic atrophy...

s first successful clinical development of a TRPV1 antagonist for DED, completed in Japan. DED, the target disease of SJP-0132, is defined as “A multifactorial disease characterized by an unstable tea...